Literature DB >> 27688802

Hydroxyurea: a new old therapy for Langerhans cell histiocytosis.

Daniel J Zinn1, Amanda B Grimes1, Howard Lin1, Olive Eckstein1, Carl E Allen1, Kenneth L McClain1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27688802      PMCID： PMC5114488          DOI： 10.1182/blood-2016-06-721993

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  22 in total

1.  High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis.

Authors:  Noah A Brown; Larissa V Furtado; Bryan L Betz; Mark J Kiel; Helmut C Weigelin; Megan S Lim; Kojo S J Elenitoba-Johnson
Journal:  Blood       Date:  2014-06-30       Impact factor: 22.113

2.  Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).

Authors:  Winfred C Wang; Russell E Ware; Scott T Miller; Rathi V Iyer; James F Casella; Caterina P Minniti; Sohail Rana; Courtney D Thornburg; Zora R Rogers; Ram V Kalpatthi; Julio C Barredo; R Clark Brown; Sharada A Sarnaik; Thomas H Howard; Lynn W Wynn; Abdullah Kutlar; F Daniel Armstrong; Beatrice A Files; Jonathan C Goldsmith; Myron A Waclawiw; Xiangke Huang; Bruce W Thompson
Journal:  Lancet       Date:  2011-05-14       Impact factor: 79.321

Review 3.  Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages.

Authors:  Jean-François Emile; Oussama Abla; Sylvie Fraitag; Annacarin Horne; Julien Haroche; Jean Donadieu; Luis Requena-Caballero; Michael B Jordan; Omar Abdel-Wahab; Carl E Allen; Frédéric Charlotte; Eli L Diamond; R Maarten Egeler; Alain Fischer; Juana Gil Herrera; Jan-Inge Henter; Filip Janku; Miriam Merad; Jennifer Picarsic; Carlos Rodriguez-Galindo; Barret J Rollins; Abdellatif Tazi; Robert Vassallo; Lawrence M Weiss
Journal:  Blood       Date:  2016-03-10       Impact factor: 22.113

Review 4.  From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera.

Authors:  S M Fruchtman; K Mack; M E Kaplan; P Peterson; P D Berk; L R Wasserman
Journal:  Semin Hematol       Date:  1997-01       Impact factor: 3.851

5.  Recurrent BRAF mutations in Langerhans cell histiocytosis.

Authors:  Gayane Badalian-Very; Jo-Anne Vergilio; Barbara A Degar; Laura E MacConaill; Barbara Brandner; Monica L Calicchio; Frank C Kuo; Azra H Ligon; Kristen E Stevenson; Sarah M Kehoe; Levi A Garraway; William C Hahn; Matthew Meyerson; Mark D Fleming; Barrett J Rollins
Journal:  Blood       Date:  2010-06-02       Impact factor: 22.113

6.  Impact of hydroxyurea on clinical events in the BABY HUG trial.

Authors:  Courtney D Thornburg; Beatrice A Files; Zhaoyu Luo; Scott T Miller; Ram Kalpatthi; Rathi Iyer; Phillip Seaman; Jeffrey Lebensburger; Ofelia Alvarez; Bruce Thompson; Russell E Ware; Winfred C Wang
Journal:  Blood       Date:  2012-08-22       Impact factor: 22.113

Review 7.  Langerhans Cell Histiocytosis: Emerging Insights and Clinical Implications.

Authors:  Daniel J Zinn; Rikhia Chakraborty; Carl E Allen
Journal:  Oncology (Williston Park)       Date:  2016-02       Impact factor: 2.990

8.  Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.

Authors:  Rikhia Chakraborty; Oliver A Hampton; Xiaoyun Shen; Stephen J Simko; Albert Shih; Harshal Abhyankar; Karen Phaik Har Lim; Kyle R Covington; Lisa Trevino; Ninad Dewal; Donna M Muzny; Harshavardhan Doddapaneni; Jianhong Hu; Linghua Wang; Philip J Lupo; M John Hicks; Diana L Bonilla; Karen C Dwyer; Marie-Luise Berres; Poulikos I Poulikakos; Miriam Merad; Kenneth L McClain; David A Wheeler; Carl E Allen; D Williams Parsons
Journal:  Blood       Date:  2014-09-08       Impact factor: 22.113

9.  Permanent consequences in Langerhans cell histiocytosis patients: a pilot study from the Histiocyte Society-Late Effects Study Group.

Authors:  Riccardo Haupt; Vasanta Nanduri; Maria Grazia Calevo; Cecilia Bernstrand; Jorge L Braier; Valerie Broadbent; Guadalupe Rey; Kenneth L McClain; Gritta Janka-Schaub; R Maarten Egeler
Journal:  Pediatr Blood Cancer       Date:  2004-05       Impact factor: 3.167

10.  BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups.

Authors:  Marie-Luise Berres; Karen Phaik Har Lim; Tricia Peters; Jeremy Price; Hitoshi Takizawa; Hélène Salmon; Juliana Idoyaga; Albert Ruzo; Philip J Lupo; M John Hicks; Albert Shih; Stephen J Simko; Harshal Abhyankar; Rikhia Chakraborty; Marylene Leboeuf; Monique Beltrão; Sérgio A Lira; Kenneth M Heym; Venetia Bigley; Matthew Collin; Markus G Manz; Kenneth McClain; Miriam Merad; Carl E Allen
Journal:  J Exp Med       Date:  2014-03-17       Impact factor: 14.307
View more
  3 in total

1.  Histiocytic disorders: insights into novel biology and implications for therapy of Langerhans cell histiocytosis and Erdheim-Chester disease.

Authors:  Kenneth McClain
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

Review 2.  Histiocytic disorders.

Authors:  Kenneth L McClain; Camille Bigenwald; Matthew Collin; Julien Haroche; Rebecca A Marsh; Miriam Merad; Jennifer Picarsic; Karina B Ribeiro; Carl E Allen
Journal:  Nat Rev Dis Primers       Date:  2021-10-07       Impact factor: 65.038

Review 3.  Langerhans cell histiocytosis in adults: Advances in pathophysiology and treatment.

Authors:  Masayuki Kobayashi; Arinobu Tojo
Journal:  Cancer Sci       Date:  2018-10-30       Impact factor: 6.716
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.